Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions
Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 911-920
DOI: 10.1093/cid/ciae550 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.11.2024. Verfasst von Matthew Davis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Rochester Clinical Research, Inc., Rochester, New York, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Older individuals and adults with certain chronic or immunocompromising health conditions are at increased risk of severe respiratory syncytial virus (RSV) disease.
Methods
In this phase 3 randomized trial of RSVpreF safety and immunogenicity in 18–59-year-olds at high risk of severe RSV disease, participants were randomized 2:1 to 1 RSVpreF (120 µg) or placebo dose. Primary safety endpoints included reactogenicity events and adverse events (AEs) through 7 days and 1 month after vaccination, respectively, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) throughout the study. In primary analyses, immunogenicity elicited 1 month after RSVpreF was bridged to a randomly selected subset of ≥60-year-olds receiving RSVpreF from the immunogenicity subset in the pivotal phase 3 RENOIR trial, which demonstrated RSVpreF efficacy. Noninferiority was declared if 95% confidence interval (CI) lower bounds were >.667 (neutralizing titer adjusted geometric mean ratios) and >−10% (seroresponse rate differences) for RSV-A and RSV-B.
Results
Overall, 678 participants received RSVpreF (n = 453) or placebo (n = 225). Most reactogenicity events were mild/moderate; severe events occurred in ≤2.0% of participants overall. AE frequencies were similar in RSVpreF (7.1%) and placebo recipients (7.6%). No vaccine-related SAEs or NDCMCs were reported. One month after RSVpreF administration, noninferiority criteria were met in 18–59-year-olds versus ≥60-year-olds for RSV-A and RSV-B neutralizing titers and seroresponse rates.
Conclusions
RSVpreF was well tolerated with no safety concerns and demonstrated immunobridging to efficacy in 18–59-year-olds at high risk of severe RSV disease versus ≥60-year-olds in whom efficacy was previously demonstrated, supporting use of RSVpreF to prevent RSV-associated disease in this population. NCT05842967.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rochester Clinical Research, Inc., Rochester, New York, USA.
- Kaiser Permanente Southern California, Los Angeles, California, USA.
- Vaccine Research & Development, Pfizer Inc, Pearl River, New York, USA.
- Vaccine Research & Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
- Vaccine Research & Development, Pfizer Ltd, Marlow, United Kingdom.
- AIM Trials, Plano, Texas, USA.
ORCID-Profile: William Towner, Elliot DeHaan, Qin Jiang, Farah Rahman, Uzma N Sarwar, Zaynah Majid-Mahomed
Förderung
- Pfizer
Zitieren
APA
Davis, M., Towner, W., DeHaan, E., Jiang, Q., Li, W., Rahman, F., Patton, M., Wyper, H., Lino, M. M., Sarwar, U. N., Majid-Mahomed, Z., Mehta, S., Howitt, W., Cannon, K., Kalinina, E., Cooper, D., Swanson, K. A., Anderson, A. S., Gurtman, A., …, & MONeT Study Team (2025). Bivalent RSVpreF Vaccine in Adults 18 to. Clinical Infectious Diseases, 80(4), 911-920. https://doi.org/10.1093/cid/ciae550
Vancouver
Davis M, Towner W, DeHaan E, Jiang Q, Li W, Rahman F, et al. Bivalent RSVpreF Vaccine in Adults 18 to. Clinical Infectious Diseases. 2025;80(4):911-920. doi:10.1093/cid/ciae550
BibTeX
@article{Davis2025,
author = {Davis, Matthew and Towner, William and DeHaan, Elliot and Jiang, Qin and Li, Wen and Rahman, Farah and Patton, Michael and Wyper, Hayley and Lino, Maria Maddalena and Sarwar, Uzma N and Majid-Mahomed, Zaynah and Mehta, Saumil and Howitt, William and Cannon, Kevin and Kalinina, Elena and Cooper, David and Swanson, Kena A and Anderson, Annaliesa S and Gurtman, Alejandra and Munjal, Iona and MONeT Study Team, MONeT Study Team},
title = {Bivalent RSVpreF Vaccine in Adults 18 to},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {4},
pages = {911--920},
doi = {10.1093/cid/ciae550}
}
EUVIMED